Gene Tan is an assistant professor at the J. Craig Venter Institute working in the Infectious Disease group. The focus of his research is on virus-host interactions by defining the immunological, molecular and genetic determinants that govern immunity and disease. The aim is to better understand how viruses manipulate the host machinery to replicate and in turn elucidate the mechanisms by which the host counteracts the pathogen. Analyses of virus-host interaction can then facilitate the development of better diagnostic tools, novel therapeutics and vaccines.
Prior to his appointment at JCVI, Dr. Tan was a postdoctoral fellow at the Icahn School of Medicine at Mount Sinai working on characterizing the immunological and structural determinants of protection against influenza virus and Zika virus. He received his doctorate from Thomas Jefferson University and his undergraduate degree from the Philadelphia College of Pharmacy and Science.
Vaccines for use in the prophylaxis and treatment of influenza virus disease (Pat. No. US20170114103)
Characterization of the structural and immunological determinants of protection against viral pathogens:
- Elucidate the mechanisms by which antibodies neutralize virus and protect in vivo.
- Emphasis on developing novel methods in isolating monoclonal antibodies from human peripheral blood mononuclear cell (PBMC) compartment.
Characterization of virus-host interaction by defining the molecular and transcriptional response
- Emphasis on respiratory and neurotropic pathogens.
Frontiers in genetics. 2023-05-09; 14.1172048.
Influenza A viruses in gulls in landfills and freshwater habitats in Minnesota, United States
Proceedings of the National Academy of Sciences of the United States of America. 2023-04-25; 120.17: e2208718120.
Epistasis reduces fitness costs of influenza A virus escape from stem-binding antibodies
Critical care (London, England). 2023-04-20; 27.1: 155.
Major adverse cardiovascular events are associated with necroptosis during severe COVID-19
Nucleic acids research. 2023-01-06; 51.D1: D678-D689.
Introducing the Bacterial and Viral Bioinformatics Resource Center (BV-BRC): a resource combining PATRIC, IRD and ViPR
STAR protocols. 2022-12-16; 3.4: 101835.
A high-throughput SARS-CoV-2 pseudovirus multiplex neutralization assay
eLife. 2022-10-14; 11.
Early immune markers of clinical, virological, and immunological outcomes in patients with COVID-19: a multi-omics study
Cell reports. Medicine. 2022-06-21; 3.6: 100640.
TNF-α+ CD4+ T cells dominate the SARS-CoV-2 specific T cell response in COVID-19 outpatients and are associated with durable antibodies
Molecular therapy : the journal of the American Society of Gene Therapy. 2022-05-04; 30.5: 2024-2047.
A single-shot adenoviral vaccine provides hemagglutinin stalk-mediated protection against heterosubtypic influenza challenge in mice
Science translational medicine. 2022-03-09; 14.635: eabm7853.
Early non-neutralizing, afucosylated antibody responses are associated with COVID-19 severity
Science translational medicine. 2022-03-02; 14.634: eabn7842.
Antibodies elicited by SARS-CoV-2 infection or mRNA vaccines have reduced neutralizing activity against Beta and Omicron pseudoviruses
Proceedings of the National Academy of Sciences of the United States of America. 2021-09-07; 118.36:
Influenza A viruses balance ER stress with host protein synthesis shutoff
Viruses. 2021-07-08; 13.7:
Evaluation of ELISA-Based Multiplex Peptides for the Detection of Human Serum Antibodies Induced by Zika Virus Infection across Various Countries
Advanced drug delivery reviews. 2021-05-01; 172.314-338.
SARS-CoV-2 vaccines in advanced clinical trials: Where do we stand?
Viruses. 2021-01-28; 13.2:
Influenza A Viruses in Whistling Ducks (Subfamily Dendrocygninae)
Nature immunology. 2021-01-01; 22.1: 67-73.
Proinflammatory IgG Fc structures in patients with severe COVID-19
Nature microbiology. 2020-09-01; 5.9: 1158-1169.
Collective interactions augment influenza A virus replication in a host-dependent manner
Nature communications. 2020-06-16; 11.1: 3132.
Author Correction: Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection
Nature communications. 2020-05-21; 11.1: 2537.
Microbiome disturbance and resilience dynamics of the upper respiratory tract during influenza A virus infection
mBio. 2020-03-24; 11.2:
Neutralizing Monoclonal Antibodies against the Gn and the Gc of the Andes Virus Glycoprotein Spike Complex Protect from Virus Challenge in a Preclinical Hamster Model
Journal of virology. 2019-10-15; 93.20:
Innate Immune Response to Influenza Virus at Single-Cell Resolution in Human Epithelial Cells Revealed Paracrine Induction of Interferon Lambda 1
Nature communications. 2018-10-11; 9.1: 4223.
Non-neutralizing antibodies elicited by recombinant Lassa-Rabies vaccine are critical for protection against Lassa fever
Nature communications. 2017-10-10; 8.1: 846.
Alveolar macrophages are critical for broadly-reactive antibody-mediated protection against influenza A virus in mice
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-18; 113.42: 11931-11936.
Epitope specificity plays a critical role in regulating antibody-dependent cell-mediated cytotoxicity against influenza A virus
Proceedings of the National Academy of Sciences of the United States of America. 2016-10-04; 113.40: E5944-E5951.
Optimal activation of Fc-mediated effector functions by influenza virus hemagglutinin antibodies requires two points of contact
Cell host & microbe. 2016-06-08; 19.6: 800-13.
Both Neutralizing and Non-Neutralizing Human H7N9 Influenza Vaccine-Induced Monoclonal Antibodies Confer Protection
PLoS pathogens. 2016-04-01; 12.4: e1005578.
Broadly-Reactive Neutralizing and Non-neutralizing Antibodies Directed against the H7 Influenza Virus Hemagglutinin Reveal Divergent Mechanisms of Protection
Journal of virology. 2016-01-13; 90.7: 3789-93.
Influenza A Viruses Expressing Intra- or Intergroup Chimeric Hemagglutinins
Antimicrobial agents and chemotherapy. 2015-07-01; 59.7: 4162-72.
Direct administration in the respiratory tract improves efficacy of broadly neutralizing anti-influenza virus monoclonal antibodies
The Journal of clinical investigation. 2015-03-02; 125.3: 1255-68.
Preexisting human antibodies neutralize recently emerged H7N9 influenza strains
Journal of virology. 2014-12-01; 88.23: 13580-92.
Characterization of a broadly neutralizing monoclonal antibody that targets the fusion domain of group 2 influenza A virus hemagglutinin
Nature medicine. 2014-02-01; 20.2: 143-51.
Broadly neutralizing hemagglutinin stalk-specific antibodies require FcγR interactions for protection against influenza virus in vivo
Journal of virology. 2012-06-01; 86.11: 6179-88.
A pan-H1 anti-hemagglutinin monoclonal antibody with potent broad-spectrum efficacy in vivo
Proceedings of the National Academy of Sciences of the United States of America. 2007-04-24; 104.17: 7229-34.
The dynein light chain 8 binding motif of rabies virus phosphoprotein promotes efficient viral transcription
Genomics of Chikungunya Virus
Sequencing Chikungunya virus genomes isolated from the Western hemisphere during the 2014 Caribbean outbreak
Genomics of Respiratory Syncytial Virus
Sequencing clinical isolates of Respiratory Syncytial Virus in various locations
Genomics of Influenza A and Influenza B Viruses
Sequencing Influenza genomes isolated from various hosts and locations